化学療法未治療の切除不能進行再発性大腸癌患者におけるmFOLFOX6 + パニツムマブ併用療法および5-FU/LV + パニツムマブ併用療法の安全性および有効性に関する研究

基本情報

NCT ID: NCT02337946
ステータス: 完了
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 164
治験依頼者名: Takeda

概要

The purpose of this study is to exploratorily examine efficacy and safety in the participants with chemotherapy-naïve unresectable, advanced/recurrent colorectal carcinoma of Kirsten rat sarcoma-2 virus (KRAS) wild-type who have been treated with 6 cycles (2 weeks/cycle) of first-line mFOLFOX6 + panitumumab combination therapy and then assigned to two groups i.e., a group receiving 5-FU/LV + panitumumab combination therapy and a group receiving mFOLFOX6 + panitumumab combination therapy.

対象疾患

Colorectal Carcinoma

介入

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab(DRUG)

依頼者（Sponsor）

武田薬品工業株式会社(INDUSTRY)